OBP2A

Across TCGA pan-cancer cohorts, OBP2A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OBP2A data layer compared with 19 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher OBP2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OBP2A expression acts as an unfavorable survival marker.

BLCA, SARC, and ESCA are the cancer types where OBP2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.090	0.572	<.001	24	view →
SARC	DFS	Median	All	0.094	0.611	.001	9	view →
ESCA	DFS	Median	II,III,IV	0.082	0.495	.002	6	view →
LUAD	DFS	Median	II,III,IV	0.098	0.682	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OBP2A–BLCA (DFS)

Open the BLCA breakdown →